Paclitaxel plus cetuximab for the treatment of R/M SCCHN after first-line pembrolizumab failure: primary analysis from the PaceAce trial
This is the first prospective trial specifically evaluating PTX plus C after failure of first-line pembrolizumab-based therapy in patients with R/M SCCHN. The observed clinical activity and tolerability support this widely available regimen as a potential standard-of-care option in the absence of randomized evidence in this setting.
Authors
- Thorsten Fuereder (ORCID: https://orcid.org/0000-0001-5356-6452)
- Luzia Berchtold (ORCID: https://orcid.org/0009-0003-5264-8562)
- Birgit Grünberger
- Andreas Ströbl (ORCID: https://orcid.org/0000-0002-3257-8611)
- Gabriele Gamerith
- Florian Kocher (ORCID: https://orcid.org/0000-0002-1027-4609)
- Thomas Melchardt (ORCID: https://orcid.org/0000-0002-0122-3631)
- Konrad Klinghammer (ORCID: https://orcid.org/0000-0001-6425-4833)
- M. Burian
- D. Hahn
- C. Wagner
- R. Greil
Institutions
- Innsbruck Medical University (AT)
- Universität Innsbruck (AT)
- Paracelsus Medical University (AT)
- Fachhochschule Wiener Neustadt (AT)
- Humboldt-Universität zu Berlin (DE)
- AGO Austria (AT)
- Klinikum Stuttgart (DE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106061
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00